Skip to main content
. Author manuscript; available in PMC: 2012 Dec 8.
Published in final edited form as: Cancer Lett. 2011 Aug 6;311(2):219–229. doi: 10.1016/j.canlet.2011.07.023

Table 1.

In vivo antitumor activity

Treatments MSC1
0.2mg/d		 Irinotecan2
100mg/kg		 Concurrent3
Combination		 Sequential4
Combination
FaDu response rate5 0% 35% 40% 100%***
A253 response rate 0% 10% 10% 40%***
1

MSC dose (0.2 mg/d × 28)

2

Irinotecan (100mg/kg/wk × 4)

3

MSC + irinotecan

4

MSC 7d prior to and then concurrently with irinotecan

5

Complete Response (CR): no detectable tumor at the site of transplant for up to 3 months after termination of treatments

***

p<0.001when compared with other groups